Inhibrx Biosciences, Inc.
INBX
$89.39
$0.290.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 1.30M | 1.40M | 1.40M | 200.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 1.30M | 1.40M | 1.40M | 200.00K |
| Cost of Revenue | 101.37M | 113.03M | 121.05M | 131.40M | 176.77M |
| Gross Profit | -100.07M | -111.73M | -119.65M | -130.00M | -176.57M |
| SG&A Expenses | 22.98M | 23.30M | 34.38M | 37.01M | 123.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 124.35M | 136.33M | 155.43M | 168.42M | 300.72M |
| Operating Income | -123.05M | -135.03M | -154.03M | -167.02M | -300.52M |
| Income Before Tax | -130.18M | -140.05M | -155.08M | -163.69M | 1.72B |
| Income Tax Expenses | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K |
| Earnings from Continuing Operations | -130.19 | -140.06 | -155.09 | -163.69 | 1.72K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.19M | -140.06M | -155.09M | -163.69M | 1.72B |
| EBIT | -123.05M | -135.03M | -154.03M | -167.02M | -300.52M |
| EBITDA | -120.71M | -132.54M | -151.42M | -164.23M | -297.92M |
| EPS Basic | -8.39 | -9.04 | -10.02 | -10.58 | 118.37 |
| Normalized Basic EPS | -5.24 | -5.65 | -6.27 | -6.61 | -12.45 |
| EPS Diluted | -8.39 | -9.05 | -10.03 | -10.59 | 116.74 |
| Normalized Diluted EPS | -5.24 | -5.65 | -6.27 | -6.61 | -12.36 |
| Average Basic Shares Outstanding | 62.06M | 61.95M | 61.88M | 61.87M | 61.02M |
| Average Diluted Shares Outstanding | 62.06M | 61.95M | 61.88M | 61.87M | 61.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |